Furthermore, in exploratory analyses of the BATTLE study, in which patients with pretreated NSCLC selleck products were randomized to four separate phase II targeted therapies including erlotinib monotherapy, clinical outcomes of patients aged >65 years were comparable with those of younger patients [12]. POLARSTAR (POst-Launch All-patient-Registration Surveillance in TARceva®-treated NSCLC patients) was a large-scale surveillance program, including all Japanese patients with NSCLC treated with erlotinib [13]. The study was undertaken

as a post-approval commitment to monitor the efficacy and safety of erlotinib in Japanese patients, and more than 10,000 patients were registered. The primary endpoints were patterns of occurrence of interstitial lung disease (ILD) and risk factors for onset of ILD, given the small but important risk in Japanese patients [8], [9] and [10]. Interim safety and efficacy data supported the clinical benefits of erlotinib in Japanese NSCLC patients, with no new safety signals observed [13]. I-BET-762 ic50 ILD (all grades) was confirmed in 4.5% of the interim analysis population with a mortality rate of 1.6%. Significant ILD risk factors included concomitant or previous ILD, smoking history, concomitant or previous lung infection, and Eastern Cooperative Oncology

Group (ECOG) performance status (PS) 2–4. The median progression-free survival (PFS) and OS were 64 and 260 days, respectively.

The present analysis of the POLARSTAR surveillance study compared the efficacy and safety of erlotinib treatment for elderly (stratified as ≥75 years or 75–84 years or ≥85 years) versus non-elderly (<75 years) Japanese patients with Alectinib NSCLC. All patients with unresectable, recurrent and/or advanced NSCLC who were treated with erlotinib in Japan between December 2007 and October 2009 were enrolled. Eligible patients received oral erlotinib (150 mg once daily) from 1027 institutions that could prescribe erlotinib (up to 12 October 2009) and were monitored until erlotinib therapy termination or completion of 12 months of treatment. The study was conducted in accordance with relevant national and local guidelines, and with ethics committee approval. Demographic and baseline data were collected for each patient, including age, gender, body mass index, tumor histology, ECOG PS, smoking history, and medical history (including hepatic dysfunction, renal dysfunction, cardiovascular disease, and lung disorders). Safety data were collected at 1, 6, and 12 months after the start of erlotinib therapy. All AE reports were collected and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 14.1 thesaurus terms.